EGRX
Eagle Pharmaceuticals, Inc.
EGRX
EGRX
Delisted
EGRX was delisted on the 2nd of October, 2024.
182 hedge funds and large institutions have $679M invested in Eagle Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 56 increasing their positions, 61 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
182
Holders Change
–
Holders Change %
0%
% of All Funds
3.95%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
20
Increased
56
Reduced
61
Closed
20
Calls
$4.74M
Puts
$9M
Net Calls
-$4.26M
Net Calls Change
-$1.32M
Top Buyers
| 1 |
LSV Asset Management
Chicago,
Illinois
|
+$8.42M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.49M |
| 3 |
SGCIA
Smith Graham & Co Investment Advisors
Houston,
Texas
|
+$4.48M |
| 4 |
SCM
Sio Capital Management
New York
|
+$4.28M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$2.98M |
Top Sellers
| 1 |
WG
Winton Group
London,
United Kingdom
|
-$9.55M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.81M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$6.51M |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$5.92M |
| 5 |
Citigroup
New York
|
-$5.36M |
